Cancer pain therapeutics market overview
The global market for cancer pain therapeutics is expected to post a healthy market growth rate of more than 9% during the forecast period. The steady growth of this market can be attributed to the launch of new products that specifically treat pain related to cancer.
Cancer pain therapeutics market driver
Technavio’s market research analyst anticipates factors such as the unmet medical needs of patients to drive the market growth during the forecast period. Currently, the drugs that are available for reducing pains associated with cancer have a prolonged duration of action and are characterized by undesirable effects like sedation and respiratory depression. Consequently, this presents an opportunity for the vendors to bring in therapies with fewer side effects and a better efficacy parameter.
Cancer pain therapeutics market projections as per geography
Geographically, the Americas are expected to account for more than 47% of the total market share by 2019. In the Americas, the US is considered to be the highest revenue-generating geography due to the recent increase in the incidence of cancer in this region.
Cancer pain therapeutics market by drug-class segmentation
- Opioids
- Non-steroidal anti-inflammatory drugs
- Others
Non-steroidal anti-inflammatory drugs are the most commonly used drugs because of their high efficacy and anti-inflammatory action. These drugs block the production of prostaglandins by inhibiting the cyclooxygenase enzyme and, therefore, reduce the pain at the site of injury.
Cancer pain therapeutics market growth analysis for key vendors
This market is highly fragmented and contains numerous competitive small and large vendors. Large vendors like BioDelivery Sciences and ProStrakan Group dominate this market during the forecast period and constantly compete with each other to gain maximum traction in this market.
Leading vendors in the cancer pain therapeutics market
- BioDelivery Sciences
- ProStrakan Group
- Teva Pharmaceuticals
Key questions answered in the report include
- What will the market size and the growth rate be in 2019?
- What are the key factors driving the global cancer pain therapeutics market?
- What are the key market trends impacting the growth of the global cancer pain therapeutics market?
- What are the challenges to market growth?
- Who are the key vendors in the global cancer pain therapeutics market?
- What are the market opportunities and threats faced by the vendors in the global cancer pain therapeutics market?
- What are the key outcomes of the five forces analysis of the global cancer pain therapeutics market?
Technavio also offers customization on reports based on specific client requirement.
Related reports
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview
- Understanding the disease
- Signs and symptoms
- Causes of cancer pain
- Assessment of cancer pain
- Treatment
- Epidemiology
PART 06: Pipeline portfolio
- Information on pipeline candidates
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by drug class
- Opioids
- Non-steroidal anti-inflammatory drugs
- Others
PART 09: Geographical segmentation
- Cancer pain therapeutics market in Americas
- Cancer pain therapeutics market in EMEA
- Cancer pain therapeutics market in APAC
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
- Competitive scenario
- Market analysis 2014
PART 16: Vendor landscape
PART 17: Key vendor analysis
- BioDelivery Sciences
- ProStrakan
- Teva Pharmaceuticals
PART 18: Appendix
PART 19: Explore Technavio